Paratek Pharmaceuticals (PRTK) Upgraded by BidaskClub to Sell

BidaskClub upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a strong sell rating to a sell rating in a report published on Saturday morning.

Several other equities research analysts have also issued reports on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price target on the stock in a research note on Wednesday, January 10th. Leerink Swann reissued an outperform rating on shares of Paratek Pharmaceuticals in a research report on Sunday, March 4th. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the company a buy rating in a research report on Thursday, April 5th. Raymond James Financial reissued an outperform rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research report on Friday, March 2nd. Finally, UBS downgraded shares of Paratek Pharmaceuticals from a strong-buy rating to an outperform rating in a research report on Friday, March 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Paratek Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $40.00.

Shares of PRTK stock opened at $13.35 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.72. Paratek Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $29.00. The firm has a market capitalization of $437.06, a price-to-earnings ratio of -4.05 and a beta of 0.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. The business had revenue of $5.07 million during the quarter, compared to analyst estimates of $5.00 million. research analysts expect that Paratek Pharmaceuticals will post -3.44 EPS for the current year.

In other news, CFO Douglas W. Pagan sold 5,237 shares of Paratek Pharmaceuticals stock in a transaction dated Monday, April 9th. The shares were sold at an average price of $12.70, for a total value of $66,509.90. Following the completion of the transaction, the chief financial officer now owns 77,083 shares of the company’s stock, valued at approximately $978,954.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Douglas W. Pagan sold 16,291 shares of Paratek Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $231,658.02. Following the completion of the transaction, the chief financial officer now directly owns 39,570 shares of the company’s stock, valued at approximately $562,685.40. The disclosure for this sale can be found here. In the last three months, insiders sold 68,385 shares of company stock valued at $925,282. Insiders own 4.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Great West Life Assurance Co. Can bought a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at about $104,000. SG Americas Securities LLC bought a new stake in shares of Paratek Pharmaceuticals during the 3rd quarter worth about $123,000. MetLife Investment Advisors LLC bought a new stake in shares of Paratek Pharmaceuticals during the 4th quarter worth about $185,000. Landscape Capital Management L.L.C. bought a new stake in shares of Paratek Pharmaceuticals during the 4th quarter worth about $221,000. Finally, Belpointe Asset Management LLC bought a new stake in shares of Paratek Pharmaceuticals during the 3rd quarter worth about $228,000. 74.44% of the stock is owned by institutional investors.

WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/17/paratek-pharmaceuticals-prtk-upgraded-by-bidaskclub-to-sell.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply